Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1007501

	registered interest
	date	14/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of (1) the economic importance of clinical trial recruitment, especially in cancer research, to the UK economy, and (2) the importance of timely molecular testing in modern cancer trial recruitment; and whether, as a result of any such assessment, NHS England will consider implementing national somatic gene testing in cancers with low survival rates to catalyse research.
	tabling member printed	Lord Freyberg
	uin	HL11501
	answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>Clinical trial recruitment is important to the United Kingdom economy, especially in cancer research. For example, an independent report, commissioned by the National Institute for Health Research (NIHR) Clinical Research Network (CRN) and produced by KPMG’s Economics team, provided an assessment of the economic impact of the NIHR Clinical Research Network’s activities to support clinical research in the UK. The report estimated the gross value added and employment in the UK from CRN supported clinical research activity. It estimated that in the period April 2014 to March 2015 (financial year 2014/15) this activity generated a total of £2.4 billion gross value added and almost 39,500 jobs. Studies on cancer comprise a major part of CRN activity. A copy of <em>NIHR Clinical Research Network: Impact and Value Assessment</em> is attached.</p><p>A growing proportion of cancer trials supported by the NIHR involve molecular testing. One of the main purposes of the NIHR is to initiate studies speedily, and deliver them to time and target. Therefore timely molecular testing is important. This involves working with National Health Service pathology services to ensure that all essential steps are in place to deliver research studies.</p><p>The Chief Scientific Adviser has not made a specific assessment of the importance of molecular testing to drive cancer trial treatment. If a clinical trial that is to be delivered by the NIHR involves somatic gene testing that is not already in place, then the NHS will set up this new somatic gene testing as part of the delivery of the trial. Thus it is the nature of the research that drives clinical trial recruitment rather than the nature of the somatic gene testing that is in place.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11502 question first answered 28/11/2018 14:50:06 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name NIHR_CRN_Impact_and_Value_Assessment.pdf title NIHR_CRN_Impact_and_Value_Assessment
	tabling member	2593 label Biography information for Lord Freyberg

1017055

	registered interest
	date	28/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 27 November (HL11452), what was the average turnaround time from sample collection to clinical report for Genomic England's somatic whole genome sequencing for cancer patients in the last six months; what is the most clinically useful timeframe from sample collection to clinical report for such genome sequencing; and how many cancer patients in Genomic England's programme have died to date without receiving their clinical report.
	tabling member printed	Lord Freyberg
	uin	HL11900
	answer	answer is ministerial correction date of answer 06/12/2018 answer text <p>Following reengineering of tumour provision to fresh tissue supply and creating 300 pathways for tumour supply across the 13 NHS Genomic Medicine Centres (GMCs), Genomics England has continued to work with the National Health Service to improve throughput over the life of the programme.</p><p>Over the past six months, the average (median) turnaround time for cancer cases from enrolment to return of analysis was 39 working days. For fast-tracked and clinically urgent cases, this average over the last six months is 25 working days. By September 2018, Genomics England were returning samples at scale in 20 days or less demonstrating the improvements in the majority of cases received.</p><p>The most clinically useful timeframe depends on each individual patient’s clinical circumstances. As the 100,000 Genomes Project is a research programme, patients were all offered the NHS standard of care for their condition, in addition to Whole Genome Sequencing, so their therapy could proceed as rapidly as needed. During the 100,000 Genomes Project about half of the cancer cases in the Project contained actionable findings identifying a potential targeted therapy or clinical trial opportunity.</p><p>To date, 5,801 participants results have been returned to NHS GMCs (some participants have multiple reports). In total, 506 participants in the 100,000 Genomes Project, many of whom had advanced disease at the time of enrolment, died before Genomics England returned a whole genome analysis to the NHS. Of these, 176 were participants who died before their DNA samples were received by Genomics England. In many cases the deceased cancer participants became part of the Project via consent by a nominated representative, relative or friend because of the value for research to help others even though it was too late for the individual concerned.</p> answering member printed Lord O'Shaughnessy question first answered 06/12/2018 14:46:02 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2593 label Biography information for Lord Freyberg

1017056

	registered interest
	date	28/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what economic modelling NHS England has carried out on the net budgetary impact of introducing a national molecular pathology service in cancer; what estimate they have made of the direct annual cost of such a service; whether they have considered switching off any legacy services to help fund its introduction; and if so, which.
	tabling member printed	Lord Freyberg
	uin	HL11901
	answer	answer is ministerial correction date of answer 06/12/2018 answer text <p>NHS England is developing a National Genomic Medicine service and this will bring together both existing clinical genetics services, and new genomic laboratory infrastructure to provide seamless service delivery for patients with rare and inherited disease and cancer. However, NHS England is not introducing a national molecular pathology service in cancer and therefore has not carried out economic modelling or an estimate of cost for such a service.</p><p>A key element of the Genomic Medicine Service is the National Genomic Test Directory which outlines the entire repertoire of genomic tests – from existing tests for single genes and molecular markers Whole Genomic Sequencing to Whole Genome Sequencing – that are available as part of the National Health Service clinical service. This includes cancer genomic tests.</p><p>As part of the NHS Genomic Medicine Service, a National Genomics Informatics System (NGIS) is being developed by Genomics England, on behalf of NHS England. When fully operational NGIS will enable NHS England to monitor the number of genomic tests being carried out across the country and benchmark activity.</p> answering member printed Lord O'Shaughnessy question first answered 06/12/2018 14:46:33 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2593 label Biography information for Lord Freyberg

1050851

	registered interest
	date	29/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to introduce national funding for cancer genomic testing in England; and if so, when.
	tabling member printed	Lord Warner
	uin	HL13269
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Building on the 100,000 Genomes Project and existing genetic services, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The aims of the GMS are to:</p><p>- Provide consistent and equitable care for the country’s 55 million population;</p><p>- Operate to common national standards, specifications and protocols;</p><p>- Deliver to a single national genomic testing directory – covering use of all technologies from single gene to whole genome sequencing initially for rare disease and cancer;</p><p>- Give all patients the opportunity to participate in research, for individual benefit and to inform future care; and</p><p>- Build a national genomic knowledge base to provide real world data to inform.</p><p>Through the GMS, NHS England will be exploring how to ensure that the funding flows for cancer support equity of access to testing across the country.</p> answering member printed Baroness Blackwood of North Oxford question first answered 12/02/2019 15:54:06 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1732 label Biography information for Lord Warner

1050852

	registered interest
	date	29/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the implications for patient access to treatment for those continuing to rely on the National Tariff Payment System to fund cancer genomic tests under the Genomic Medicine Service in England.
	tabling member printed	Lord Warner
	uin	HL13270
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Funding for cancer genomic testing is included under the National Tariff Payment System, excluding whole genome sequencing which NHS England is funding nationally, and is included within the healthcare resource group tariff payment for an individual patient. For example, epidermal growth factor receptor (EGFR) testing for lung cancer, along with oestrogen (positive/negative progesterone) receptor status and human epidermal growth factor receptor 2 (HER2) testing for breast cancer have been established tests within the National Health Service for a number of years.</p><p>Cancer genomic testing will continue to be funded by the National Tariff Payment System and the National Genomic Test Directory outlines the cancer genomic tests which will be delivered by the NHS in England.</p> answering member printed Baroness Blackwood of North Oxford question first answered 12/02/2019 15:54:47 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1732 label Biography information for Lord Warner

1050853

	registered interest
	date	29/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking, or plan to take, to mitigate the possibility of variation in patient access to cancer genomic testing in England resulting from Clinical Commissioning Group decision-making.
	tabling member printed	Lord Warner
	uin	HL13271
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The <em>Annual Report of the Chief Medical Officer 2016: Generation Genome</em>, made clear that in order to achieve equitable access to genomic testing the National Health Service will need to implement a first-class genomic medicine service that is scalable, future proof and delivers value for money. The report also noted the work undertaken as part of the 100,000 Genomes Project. A copy of the report is attached.</p><p>Therefore, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The aims of the GMS are to:</p><p>- Provide consistent and equitable care for the country’s 55 million population;</p><p>- Operate to common national standards, specifications and protocols;</p><p>- Deliver to a single national genomic testing directory – covering use of all technologies from single gene to whole genome sequencing initially for rare disease and cancer;</p><p>- Give all patients the opportunity to participate in research (for individual benefit and to inform future care); and</p><p>- Build a national genomic knowledge base to provide real world data to inform.</p><p>A key element of the GMS is the National Genomic Test Directory which outlines the entire repertoire of genomic tests for cancer and rare and inherited disease – from Whole Genomic Sequencing to panel tests, to tests for single genes and molecular markers – that are available as part of the NHS clinical service in England.</p><p>The NHS GMS will be supported by an informatics system, that is being developed in partnership with Genomics England. When fully operational the National Genomics Informatics Service will enable NHS England to monitor the number of genomic tests being carried out across the country and benchmark activity.</p> answering member printed Baroness Blackwood of North Oxford question first answered 12/02/2019 16:06:53 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name HL13271 - Lord Warner - CMO_annual_report_generation_genome.pdf title CMO Annual Report 2016 Generation Genome
	tabling member	1732 label Biography information for Lord Warner

1147651

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to increase the uptake of checks for breast, bowel, and cervical diseases; and whether they intend to publish guidance to NHS trusts in England about ways in which such trusts can increase the uptake of such checks.
	tabling member printed	Baroness Redfern
	uin	HL17977
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England is committed to improving the uptake of national cancer screening programmes, for breast, bowel, and cervical cancer.</p><p>In January, NHS England published its Long Term Plan, which outlined its ambition to deliver improvements in the uptake of national cancer screening programmes. To support this process, NHS England has developed improving uptake action plans, which can be used by providers and the wider health system, to improve the performance of screening programmes.</p><p>The uptake action plans include proposals for reviewing and extending appointment hours (for example for breast cancer screening) and using data to inform strategies for improving uptake in those populations of greatest need. These plans are already available to commissioning teams and will be updated and reissued throughout the year.</p><p>National Health Service regions are currently developing implementation plans to deliver on these commitments. To provide robust oversight and assurance of delivery, NHS England has established national programme boards for each cancer screening programme area.</p><p>In addition, we expect the Sir Mike Richards’ Review of Screening report, due to be published soon, to identify additional opportunities to improve the uptake of breast, bowel, and cervical screening.</p><p>Further, Public Health England has been running ‘Be Clear on Cancer’ campaigns since 2011. These are designed to raise the public’s awareness of specific cancer symptoms; encourage people with those symptoms to go to the doctor; and diagnose cancer at an earlier stage, and therefore make it more treatable, and thereby improve cancer survival rates.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:40:48 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4551 label Biography information for Baroness Redfern

1147652

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what consideration they have given to using (1) smartphone bookings, (2) text reminders, (3) evening appointments, and (4) accessible locations, for cancer screening appointments; and what assessment, if any, they have made of whether such measures would increase (a) the uptake of such screenings, and (b) early diagnosis.
	tabling member printed	Baroness Redfern
	uin	HL17978
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England recognises the importance of delivering public health services, including screening, which people find easy to access. This is why the NHS Long Term Plan and detailed improvement actions are about ensuring services are easy and convenient for people to use in order to deliver the Long Term Plan ambition on cancer to see 55,000 more people surviving cancer for five years in England each year from 2028.</p><p>The actions plans include real-world case studies which have demonstrated improvements in local areas. These case studies sit alongside widely published evidence which has been proven to deliver improvements in uptake. We expect these actions to have a positive impact on the uptake of screening.</p><p>Sir Mike Richards’ Review of Screening report is due to be published shortly which will identify additional opportunities to improve the uptake of breast, bowel, and cervical screening. In addition, NHSX is looking at possible improvements to screening IT systems, which should support the delivery of cancer screening programmes.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:41:24 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4551 label Biography information for Baroness Redfern

1625809

	registered interest
	date	03/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what is the national target time for (1) analysis, and (2) assessment, of biopsy results for patients being treated for cancer-related conditions; and what assessment they have made of whether the Royal Berkshire Hospital in Reading is meeting these.
	tabling member printed	Lord Campbell-Savours
	uin	HL7619
	answer	answer is ministerial correction date of answer 23/05/2023 answer text <p>There is no national target time for analysis and assessment of biopsy results for patients being treated for cancer related conditions.</p> answering member printed Lord Markham question first answered 23/05/2023 14:26:44 answering member 4948 label Biography information for Lord Markham
	tabling member	499 label Biography information for Lord Campbell-Savours

1625810

	registered interest
	date	03/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the impact of a delay of seven weeks for the (1) analysis, and (2) assessment, of stage 3 cancer biopsy results on patients potentially under treatment for cancer.
	tabling member printed	Lord Campbell-Savours
	uin	HL7620
	answer	answer is ministerial correction date of answer 22/05/2023 answer text <p>No assessment has been made by the Department of Health and Social Care.</p> answering member printed Lord Markham question first answered 22/05/2023 16:42:17 answering member 4948 label Biography information for Lord Markham
	tabling member	499 label Biography information for Lord Campbell-Savours